Tenax Therapeutics Nears Critical Data Readout Following Enrollment Success

Tenax Therapeutics completes enrollment for its pivotal LEVEL study. Topline results for TNX-103 in PH-HFpEF, an untreatable condition, are expected in Q3 2026, with cash runway into 2027.

Tenax Therapeutics is approaching a pivotal moment for its lead drug candidate. The company recently surpassed a key enrollment target in early March, setting the stage for highly anticipated clinical trial results. The development program for its oral therapy, TNX-103 (levosimendan), is now entering its most consequential evaluation period.

The focus is on the completion of the LEVEL study, a Phase 3 trial investigating the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). This condition currently lacks any approved therapies, heightening the significance of the trial. Tenax has already randomized more than the initial target of 230 patients. The final screening activities are scheduled to conclude by the end of March.

Financial and Intellectual Property Foundation

From a financial perspective, Tenax appears positioned to fund its operations through this crucial phase. According to recent reports, the company's existing cash reserves are projected to be sufficient to sustain operations into 2027. This liquidity is earmarked for advancing the ongoing Phase 3 programs and expanding the clinical pipeline.

Furthermore, the company has strengthened its intellectual property portfolio. It has secured extended patent protection for subcutaneous formulations of levosimendan. Such expansions are generally viewed by industry observers as a key element for maintaining a competitive edge within the specialized cardiovascular pharmaceutical niche.

A Roadmap Defined by Key Milestones

The clinical timeline is now centered on several upcoming catalysts. The completion of patient randomization for the LEVEL study is expected by the end of March 2026. Subsequently, the first topline results from this Phase 3 trial are planned for release in the third quarter of 2026. These data will be fundamental in determining the regulatory pathway and commercial potential for TNX-103.

In parallel, management is progressing the global LEVEL-2 study. This second registrational trial is designed to support the long-term clinical strategy. Patient recruitment for LEVEL-2 is anticipated to continue through the end of 2027.

The forthcoming data readout in late 2026 represents the most immediate and significant milestone for Tenax Therapeutics, with the potential to redefine the treatment landscape for PH-HFpEF patients.